TICKERNERD
Menu
ARMPARMPHealthcare · Biotechnology

ARMP Stock Forecast: Armata Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$4.56
−5.39% on the day

The 2 Wall Street analysts covering Armata Pharmaceuticals, Inc. hold a median 12-month price target of $18 — +283.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 66 of 100 as at 15 Aug 2026 — in the upper half.

Market cap
$167.4M
Ticker Nerd rank
66 / 100
Median analyst target
$18
Analysts covering
2
Total return, dividends reinvested
1W
−3.2%
1M
+16.3%
YTD
−27.4%
1Y
+80.2%
From 52W high
−69.2%
From 52W low
+87.7%
$2
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ARMP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Armata Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
66 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
95
Value
82
Size
70
Momentum
67
Revisions
62
Volatility
50
Quality
48
Growth
27
Issuance
15

Accruals (95): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (15): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ARMP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ARMP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20Oct 25Jan 26Apr 26Jul 26ARMPHigh $20Median $18Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $15Median $18High $20

The green dot is the last close — the median target sits +283.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
23 Feb 2026HC Wainwright & Co.MaintainsBuy—
5 Jan 2026Jones TradingInitiatesBuy—
19 May 2025HC Wainwright & Co.MaintainsBuy—
19 Dec 2024HC Wainwright & Co.ReiteratesBuy—
14 Nov 2024HC Wainwright & Co.ReiteratesBuy—
12 Nov 2024HC Wainwright & Co.ReiteratesBuy—
15 Aug 2024HC Wainwright & Co.ReiteratesBuy—
11 July 2024HC Wainwright & Co.ReiteratesBuy—
8 May 2024HC Wainwright & Co.ReiteratesBuy—
22 Mar 2024HC Wainwright & Co.MaintainsBuy—
14 Aug 2023HC Wainwright & Co.ReiteratesBuy—
12 May 2023HC Wainwright & Co.ReiteratesBuy—
17 Mar 2023HC Wainwright & Co.ReiteratesBuy—
7 Mar 2023HC Wainwright & Co.ReiteratesBuy—
22 Mar 2021HC Wainwright & Co.MaintainsBuy—
15 May 2020H.C. WainwrightReiteratesBuy—
15 May 2020HC Wainwright & Co.ReiteratesBuy—
20 Mar 2020H.C. WainwrightReiteratesBuy—
20 Mar 2020HC Wainwright & Co.ReiteratesBuy—
6 Feb 2020Maxim GroupInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ARMP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ARMP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Armata Pharmaceuticals, Inc. (ARMP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.9×

Cheaper than 82% of US stocks

Price / sales
30.2×

Cheaper than 7% of US stocks

Price / book
−0.5×

Cheaper than 94% of US stocks

EV / EBITDA
−13.6×

Cheaper than 86% of US stocks

Growth & margins
Revenue growth (YoY)
15.7%

Higher than 64% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−410.8%

Higher than 8% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
79.5%

Higher than 95% of US stocks

Return on assets
−25.8%

Higher than 16% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ARMP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ARMPArmata Pharmaceuticals, Inc.$167.4M
66
CDXSCodexis, Inc.$167.8M
70
NKTXNkarta, Inc.$166.1M
40
CRBUCaribou Biosciences, Inc.$169.4M
60
HUMAHumacyte, Inc.$163.1M
18
OKUROnKure Therapeutics, Inc.$161.1M
55
CNTBConnect Biopharma Holdings Ltd.$160.6M
20

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Armata Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ARMP news & analysis

Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update

PRNewsWire · 12 Aug 2026neutral

Armata Pharmaceuticals announced its financial results for the second quarter ended June 30, 2026, and provided a corporate update. The company reported that it continues to finalize activities required to initiate a pivotal Phase 3 superiority study of its bacteriophage therapeutic AP-SA02 in complicated Staphylococcus aureus infections.

Why it matters — The update signals that Armata is moving forward with the preparation of a pivotal Phase 3 study of AP-SA02, a key late-stage program for its pathogen-specific bacteriophage therapeutics.

FAQ

Frequently asked questions about ARMP stock

What is the ARMP stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Armata Pharmaceuticals, Inc. have a median 12-month price target of $18, with estimates ranging from $15 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ARMP stock a buy right now?

Of the 2 analysts covering Armata Pharmaceuticals, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Armata Pharmaceuticals, Inc. 66 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ARMP?

As at 15 Aug 2026, Armata Pharmaceuticals, Inc. ranks 66 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (95 of 100).

Will ARMP stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +283.8% from the last close, and Ticker Nerd's factor model ranks Armata Pharmaceuticals, Inc. 66 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ARMP stock forecast for 2030?

No analyst covering Armata Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARMP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $20 over the next 12 months.

How has ARMP stock performed over the past year?

Armata Pharmaceuticals, Inc. returned +80.2% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Armata Pharmaceuticals, Inc. do?

Armata Pharmaceuticals Inc. is a biotechnology company dedicated to the development of innovative therapies to treat antibiotic-resistant infections.

What is the latest news on ARMP?

The most recent item we track (PRNewsWire, 12 Aug 2026): "Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update". Armata Pharmaceuticals announced its financial results for the second quarter ended June 30, 2026, and provided a corporate update. The company reported that it continues to finalize activities required to initiate a pivotal Phase 3 superiority study of its bacteriophage therapeutic AP-SA02 in complicated Staphylococcus aureus infections.

Company

About Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals Inc. is a biotechnology company dedicated to the development of innovative therapies to treat antibiotic-resistant infections. Operating in the healthcare sector, the company focuses on bacteriophage-based solutions, aiming to address the growing global issue of antimicrobial resistance. Armata Pharmaceuticals specializes in researching and developing treatments derived from natural phages, viruses that specifically target and eliminate bacteria, offering an alternative to traditional antibiotics. The company’s efforts are crucial in fields impacted by resistant bacterial strains, including healthcare-associated infections and chronic illnesses linked to bacterial biofilms. With its headquarters in the United States, Armata engages in collaborations with various research institutions and industry partners, emphasizing a scientific approach alongside cutting-edge technology. Armata Pharmaceuticals holds a significant position in the biopharmaceutical market, contributing to the advancement of precision medicine and public health innovations. Its dedication to addressing unmet medical needs positions it as a key player in the development of next-generation antimicrobial therapies. By exploring bacteriophage technology, Armata aims to provide targeted, effective alternatives that could revolutionize how infections are managed globally.

CEO Dr. Deborah L. Birx M.D. · 61 employees · United States · https://www.armatapharma.com